Diligence memo · auto-generated · as of July 2, 2026
Sana Biotechnology, Inc.
Sana Biotechnology, Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Sana Biotechnology, Inc. operates in Biotechnology, based in SEATTLE. Sana is creating engineered cells to repair and control genes in cells or replace missing or damaged cells to solve the underlying causes of disease.
Sub-sector tags: ai/ml, biotech, healthtech, pharma.
Capital & rounds (filed)filed
Sana Biotechnology, Inc. has raised $867M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Growth/Late (a round over $400M).
Largest single filing: $821M on 2019-02-13.
Most recent recorded round closed around 2019-02-13.
Valuation (modeled)modeled
Provath models Sana Biotechnology, Inc. at approximately $34.8B (range $5.1B–$62.7B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.83× the median modeled value of Growth/Late Biotechnology companies in 2019–2021 (5 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 4 months.
Last raise 7.4 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 17.9× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 100% of Biotechnology peers (4293 compared).
Modeled value ranks above 100% of those peers.
Closest niche peers: National Resilience, Inc., Neumora Therapeutics, Inc., Intarcia Therapeutics, Inc, Vaxxinity, Inc..
Peoplefiled
12 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.